Unlocking the next wave of cancer vaccines: Advancing mRNA-LNP delivery and small-scale manufacturing
Personalized cancer vaccines (PCVs) are reshaping immuno-oncology. However, translating these therapies into the clinic remains challenging. The progress is often slowed by critical bottlenecks – from suboptimal delivery, limited access to novel lipid nanoparticle (LNP) formulations, to a lack of manufacturing technologies designed for small-scale clinical production.
This webinar explores how optimized ionizable LNP formulations improve the delivery of multi-epitope mRNA cancer vaccine candidates while supporting safety and immune-targeted expression. We will share findings from repeat intramuscular dosing studies demonstrating favorable tolerability and extended survival in tumor‑bearing mice.
You will also learn how pairing advanced LNP design with small‑scale clinical manufacturing technologies enables a smoother transition from early development to clinical evaluation. By aligning formulation strategy with scalable process designs, teams can ensure PCV candidates are potent and ready for clinical translation.
Join this webinar to learn:
~ Why current PCV delivery strategies fall short—and how next-generation ionizable lipid formulations address safety and tissue-targeting limitations
~ How optimized ionizable lipids enhance effective LNP-mediated delivery, mRNA translation, and antigen presentation for multi‑epitope mRNA cancer vaccines
~ Key findings from repeated intramuscular dosing studies, including maintained critical quality attributes (CQAs), no detectable toxicity, and extended survival in tumor‑bearing mice
~ Practical considerations for building PCV manufacturing workflows that transition seamlessly from concept to clinic using technologies purpose-built for small-scale clinical production
Speaker:
Martin Rabel
Global Sales Specialist, BioPharma Services, Cytiva
Martin Rabel, Ph.D., leads the commercial strategy for Cytiva’s BioPharma Services portfolio across EMEA and APAC. In this role, he supports the advancement of nucleic acid–based therapies by enabling access to Cytiva’s proprietary lipid nanoparticle (LNP) platform and its integrated suite of nanoparticle development, analytical, and cGMP-compliant manufacturing services.
Martin plays a key part in shaping and expanding this rapidly growing area of Cytiva’s offering. With a background as a trained Pharmacist and deep technical expertise in nanomedicine and RNA–LNP technologies, he is committed to delivering exceptional customer guidance along with strong scientific and commercial excellence.
